A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT05864144. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (Anti VISTA) as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Study identification
- NCT ID
- NCT05864144
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Sensei Biotherapeutics, Inc.
- Industry
- Enrollment
- 98 participants
Conditions and interventions
Conditions
- Advanced Cancer
- Advanced Solid Tumor
- Bladder Cancer
- Breast Cancer
- Cervix Cancer
- Colon Cancer
- Esophageal Cancer
- Gastric Cancer
- Head and Neck Cancer
- Kidney Cancer
- Melanoma
- Merkel Cell Carcinoma
- Metastatic Cancer
- Non Small Cell Lung Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer
- Refractory Cancer
- Sarcoma
- Solid Tumor, Adult
- Thyroid Cancer
- Uterine Cancer
Interventions
- Cemiplimab Drug
- SNS-101 (anti-VISTA) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 30, 2023
- Primary completion
- May 31, 2027
- Completion
- May 31, 2027
- Last update posted
- Aug 14, 2025
2023 – 2027
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA Hematology/Oncology | Los Angeles | California | 90095 | — |
| University of Colorado Cancer Center - Anschutz Medical | Aurora | Colorado | 80045 | — |
| Norton Healthcare | Louisville | Kentucky | 40202 | — |
| Henry Ford Cancer | Detroit | Michigan | 48202 | — |
| Icahn School of Medicine at Mt. Sinai | New York | New York | 10029 | — |
| University of Pennsylvania, Perelman Center for Advanced Medicine | Philadelphia | Pennsylvania | 19104 | — |
| Sanford Cancer Center | Sioux Falls | South Dakota | 57104 | — |
| NEXT Oncology Dallas | Irving | Texas | 75039 | — |
| South Texas Accelerated Research Therapeutics (START) San Antonio | San Antonio | Texas | 78229 | — |
| START Mountain Region | West Valley City | Utah | 84119 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05864144, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 14, 2025 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05864144 live on ClinicalTrials.gov.